{"nctId":"NCT02420262","briefTitle":"A Clinical Trial Comparing Efficacy and Safety of Insulin Degludec/Liraglutide (IDegLira) Versus Basal-bolus Therapy in Subjects With Type 2 Diabetes Mellitus","startDateStruct":{"date":"2015-07-26","type":"ACTUAL"},"conditions":["Diabetes","Diabetes Mellitus, Type 2"],"count":506,"armGroups":[{"label":"IDegLira","type":"EXPERIMENTAL","interventionNames":["Drug: insulin degludec/liraglutide"]},{"label":"IGlar plus IAsp","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: insulin glargine","Drug: insulin aspart"]}],"interventions":[{"name":"insulin degludec/liraglutide","otherNames":[]},{"name":"insulin glargine","otherNames":[]},{"name":"insulin aspart","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female, age at least 18 years at the time of signing informed consent\n* Type 2 diabetes subjects (diagnosed clinically) at least 6 months prior to screening\n* HbA1c (glycosylated haemoglobin) 7.0-10.0% \\[53mmol/mol-86mmol/mol\\] (both inclusive) by central laboratory analysis\n* Current treatment with IGlar (insulin glargine) for at least 90 calendar days prior to screening\n* Stable daily dose of IGlar between 20 units and 50 units (both inclusive) for at least 56 calendar days prior to screening. Individual fluctuations of plus/minus 10% within the 56 calendar days prior to screening are acceptable, however on the day of screening total daily dose should be within the range of 20 units-50 units both inclusive\n* Stable daily dose of metformin (at least 1500 mg or max tolerated dose) for at least 90 calendar days prior to screening\n* Body mass index (BMI) below or equal to 40 kg/m\\^2\n\nExclusion Criteria:\n\n* Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria in a period of 90 calendar days before screening\n* Anticipated initiation or change in concomitant medications in excess of 14 calendar days known to affect weight or glucose metabolism, such as weight loss/modifying (e.g.; sibutramine, orlistat, thyroid hormones, corticosteroids)\n* Impaired liver function, defined as alanine aminotransferase (ALT) at least 2.5 times upper limit of normal\n* Renal impairment eGFR (electronic case report form) below 60 mL/min/1.73 m\\^2 as per CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration)\n* Screening calcitonin at least 50 ng/L\n* History of pancreatitis (acute or chronic)\n* Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in HbA1c (Glycosylated Haemoglobin)","description":"Change in HbA1c values after 26 weeks of treatment.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.48","spread":"0.05"},{"groupId":"OG001","value":"-1.46","spread":"0.05"}]}]}]},{"type":"SECONDARY","title":"Number of Treatment Emergent Severe or Blood Glucose Confirmed Symptomatic Hypoglycaemic Episodes.","description":"Severe or blood glucose (BG) confirmed symptomatic hypoglycaemic episodes were defined as episodes that were severe and/or BG confirmed by a plasma glucose value of \\<56 mg/dL (3.1 mmol/L), with symptoms consistent with hypoglycaemia.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"129","spread":null},{"groupId":"OG001","value":"975","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Body Weight","description":"Change in body weight after 26 weeks of treatment.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.93","spread":"0.22"},{"groupId":"OG001","value":"2.64","spread":"0.22"}]}]}]},{"type":"SECONDARY","title":"Responder for HbA1c Below 7.0%","description":"Number of subjects with HbA1c below 7% after 26 weeks of treatment.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"157","spread":null},{"groupId":"OG001","value":"156","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"81","spread":null},{"groupId":"OG001","value":"77","spread":null}]}]}]},{"type":"SECONDARY","title":"Responder for HbA1c Below or Equal to 6.5 %","description":"Number of subjects with HbA1c below 6.5% after 26 weeks of treatment.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"118","spread":null},{"groupId":"OG001","value":"104","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"120","spread":null},{"groupId":"OG001","value":"129","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":12,"n":252},"commonTop":["Nasopharyngitis","Headache","Nausea","Upper respiratory tract infection","Influenza"]}}}